Ono Pharmaceutical Co., Ltd.
OPHLF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.02 | 0.21 | -1.05 |
| FCF Yield | 6.89% | 0.18% | 4.81% | 1.06% |
| EV / EBITDA | 16.67 | 20.20 | -124.96 | 29.24 |
| Quality | ||||
| ROIC | 2.37% | 1.85% | -0.58% | 1.28% |
| Gross Margin | 73.02% | 70.98% | 59.72% | 65.85% |
| Cash Conversion Ratio | 2.28 | 0.19 | -5.96 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.48% | 2.56% | 2.87% | 4.35% |
| Free Cash Flow Growth | -70.18% | -97.01% | 398.61% | -76.92% |
| Safety | ||||
| Net Debt / EBITDA | -1.29 | -0.03 | 10.00 | -0.28 |
| Interest Coverage | 24.29 | 0.00 | -6.03 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.51 | 0.52 | 0.60 | 0.59 |
| Cash Conversion Cycle | 106.41 | 119.82 | 79.42 | 134.45 |